Compass Therapeutics, Inc.
Financials
Valuation Metrics
Compass Therapeutics, Inc.'s Market Cap is $138M. At end of 2025 it was $993M. Ranked #3026 of 3,118 in US market (top 97%), #1394 of 1,474 on NASDAQ (top 95%), #252 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $138M | US#3,026/3,118 Sec#252/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-73M | US—/3,118 Sec—/265 |
| Total Assets | $190M | US#2,991/3,118 Sec#247/265 |
| Net Assets | $166M | US#2,714/3,118 Sec#199/265 |
| Employees | 39 | US#2,720/3,118 Sec#213/265 |
| Value | ||
| P/B | 0.83x | US#296/3,118 Sec#15/265 |
| FCF Yield | -39.83% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -44.23% | US#2,648/3,118 Sec#147/265 |
| ROA | -38.62% | US#2,934/3,118 Sec#186/265 |
| Financial Health | ||
| Debt Ratio | 14.53% | US#166/3,118 Sec#66/265 |
| Total Debt | $10M | US#2,824/3,118 Sec#198/265 |
| FCF | $-55M | US#2,531/3,118 Sec#117/265 |
| Cash | $35M | US#2,705/3,118 Sec#241/265 |
| Current Ratio | 11.22x | US#215/3,118 Sec#67/265 |
| Performance | ||
| 1Y Return | -79.48% | US#3,070/3,118 Sec#257/265 |
| 1M Return | -10.41% | US#2,877/3,118 Sec#237/265 |
| From 52W High | -88.84% | US#3,097/3,118 Sec#257/265 |
| 1Y MDD | -88.83% | US#3,098/3,118 Sec#257/265 |
| Trading | ||
| Volume | 2,040,846 shares | US#759/3,118 Sec#62/265 |
| Trading Value | $2M | US#2,881/3,118 Sec#239/265 |
| Per Share | ||
| EPS | $-0.41 | US—/3,118 Sec—/265 |
| BPS | $0.92 | US#2,703/3,118 Sec#204/265 |
Company Info
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.